outpace logo.png
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
August 01, 2024 09:00 ET | Outpace Bio
Seattle, WA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- – Financing syndicate led by RA Capital Management with significant support from a world-class group of existing and new healthcare investors –...
main.png
AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer
August 09, 2023 09:00 ET | Renovaro Biosciences Inc.
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer In silico detection for 12 additional cancers, including pancreaticMore than 2,600 proprietary...
Black-Enochian-Primary-Logo.jpg
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
June 08, 2023 08:45 ET | Enochian BioSciences, Inc.
LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application...
outpace logo.png
Outpace Bio to Present New Data on OutSmart™ IL-2/15, a CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity, at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 18, 2023 08:00 ET | Outpace Bio
Seattle, WA, May 18, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced it will...
Outpace Bio, a Leader in Protein Design for Cell Therapy, Announces Presentation at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 09, 2023 09:00 ET | Outpace Bio
Seattle, WA, May 09, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced that an...
Black-Enochian-Primary-Logo.jpg
Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform
October 17, 2022 08:30 ET | Enochian BioSciences, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Today, Enochian BioSciences (the Company) announced that it was awarded a U.S. patent for its proprietary cancer treatment platform that could...
Flerie Logo 3.png
Flerie Invest AB leads $52m acquisition of Swedish Biopharma Facility from Charles River
October 15, 2021 01:00 ET | FLERIE INVEST AB
STOCKHOLM, Sweden, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Flerie Invest, a biotech and pharma investment firm with offices in Stockholm and London, led a syndicate of investors in the $52m acquisition of...
Black-Enochian-Primary-Logo.jpg
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential HIV Cure
June 14, 2021 07:00 ET | Enochian Biosciences, Inc.
LOS ANGELES, June 14, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that...
EnochianLogo-2000x1607px.jpg
Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy
March 24, 2021 18:00 ET | Enochian Biosciences, Inc.
LOS ANGELES, March 24, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Seraph Research Institute (SRI) and Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in...
EnochianLogo-2000x1607px.jpg
Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference
February 22, 2021 17:15 ET | Enochian Biosciences, Inc.
LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will...